{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.50","value":"22.9"},{"groupId":"OG001","spread":"4.42","value":"23.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.04","value":"-0.8"},{"groupId":"OG001","spread":"3.20","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"Change at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.11","value":"-1.0"},{"groupId":"OG001","spread":"2.63","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"Change at Week 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.26","value":"-1.1"},{"groupId":"OG001","spread":"2.97","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Change at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"-0.8"},{"groupId":"OG001","spread":"4.48","value":"-0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Change at Week 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.23","value":"-1.7"},{"groupId":"OG001","spread":"2.90","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"Change at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.89","value":"-2.5"},{"groupId":"OG001","spread":"2.67","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"title":"Change at Week 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.37","value":"-2.5"},{"groupId":"OG001","spread":"3.18","value":"0.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Change at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.50","value":"-1.8"},{"groupId":"OG001","spread":"3.13","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at Week 37"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.94","value":"-1.5"},{"groupId":"OG001","spread":"2.80","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Change at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.72","value":"-2.0"},{"groupId":"OG001","spread":"3.59","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Change at Week 45"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.78","value":"-0.9"},{"groupId":"OG001","spread":"2.12","value":"0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Change at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.78","value":"-0.2"},{"groupId":"OG001","spread":"2.85","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at Week 53"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.25","value":"-0.4"},{"groupId":"OG001","spread":"2.37","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Change at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"-0.8"},{"groupId":"OG001","spread":"2.32","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Change at Week 61"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.25","value":"-1.9"},{"groupId":"OG001","spread":"1.99","value":"0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Change at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.08","value":"-0.3"},{"groupId":"OG001","spread":"2.67","value":"-0.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Week 69"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.05","value":"-0.3"},{"groupId":"OG001","spread":"5.66","value":"-3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.81","value":"-0.7"},{"groupId":"OG001","spread":"4.24","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Week 77"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.12","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change at Week 81"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.00","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change at Week 85"},{"categories":[{"measurements":[{"comment":"As only 1 participant was analyzed at Week 89, standard deviation could not be calculated.","groupId":"OG000","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Change at Week 89"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with confirmed PSA progression at Week 21 in open label period, received enzalutamide 160 mg as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in double blind treatment period, up to disease progression (as defined by radiographic imaging or unequivocal clinical progression or death on study), intolerable toxicity, or participant withdrawal, whichever occurred first. Participants were followed up for 16 weeks at 4-week interval after discontinuation of study drug for survival and subsequent antineoplastic therapy for prostate cancer.","id":"OG000","title":"Enzalutamide 160mg+Abiraterone 1000mg+ Prednisone 10mg"},{"description":"Participants with confirmed PSA progression at Week 21 in open label period, received placebo matched to enzalutamide as four 40 mg capsules, orally once daily along with abiraterone 1000 mg as four 250-mg tablets, orally once daily and prednisone 5 mg tablet, orally twice daily in double blind treatment period, up to disease progression (as defined by radiographic imaging or unequivocal clinical progression or death on study), intolerable toxicity, or participant withdrawal, whichever occurred first. Participants were followed up for 16 weeks at 4-week interval after discontinuation of study drug for survival and subsequent antineoplastic therapy for prostate cancer.","id":"OG001","title":"Placebo+Abiraterone 1000mg+ Prednisone 10mg"}],"paramType":"MEAN","populationDescription":"ITT population included all participants randomly assigned to study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89","title":"Change From Baseline in Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) Physical Well-Being Domain Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}